Dec 11, 2023 · 23m · a16z

Big Ideas in 2024: Democratizing “Miracle Drugs” with Julie Yoo

0:00 / 0:00

gold bands on the timeline = statements, start to end. Hover to read, click to jump. CC turns on captions

In this episode of the a16z Podcast, General Partner Julie Yoo discusses the critical technological, financial, and logistical breakthroughs required to democratize access to miracle drugs like GLP-1s and cell and gene therapies in 2024. She explores how startup innovation across biomanufacturing, healthcare fintech, and policy reform can overcome system bottlenecks to scale life-changing medical advancements.

Chapters · click to jump

1 statement ▾

Yoo: US healthcare system cannot bear costs of breakthrough therapies open →

2 statements ▾

Julie Yoo: Type 2 diabetes affects over 11% of Americans open →

Julie Yoo: Obesity affects 42% of the American population open →

3 statements ▾

Yoo: Humira was history's best-selling US drug, treating 300,000 annually open →

Yoo: GLP-1s logged 3.6 million US prescription claims in 2022 open →

Yoo: Only 25% of employer health plans cover GLP-1 drugs open →

1 statement ▾

Yoo: Dozens of cell and gene therapies will reach market soon open →

1 statement ▾

Yoo: Cell and gene therapies cost $2M to $3M upfront open →

2 statements ▾

Yoo: GLP-1 drugs cost health plans roughly $1,000 per month open →

Yoo: Cheaper GLP-1 alternatives expected to be approved within years open →

1 statement ▾

Yoo: Drug makers lack post-market data feedback loops for prescriptions open →

1 statement ▾

Yoo: CMS will launch payment guidance for breakthrough therapies despite election delays open →

How this conversation actually went

Every chapter scored 0–10 on four independent dynamics. Hover any point for the reasoning behind the score. How this is scored →

The host as informed peer 2.0 Guest teaching 4.8 Guest disagreement 0.2 The host pushing back 0.1

speaking balance: gold is the host, purple is the guest (3 minute bins)

Sharpest disagreement ▶ 8:21 Gentle reframing of host comparison

In a very collaborative interview, this brief reframe represents the guest's mildest pushback, gently countering that cell and gene therapies present an even more extreme version of the operational challenge than GLP-1s.

Hardest push from the host ▶ 20:48 Host re-focuses guest on policy role

The host calls back to her previous unaddressed question on policy, pressing the guest to clarify whether private startup innovation alone can thread the needle or if government regulation is mandatory.

Biggest teaching moment ▶ 11:49 Structural mismatch of drug cost vs employee tenure

The guest delivers a clear educational breakdown revealing why insurers resist $2-3M upfront drug payments when average employee tenure at a company is only 3-4 years.

The host holds their own ▶ 15:15 Host articulates broader philosophical and downstream health impacts

The host demonstrates strong synthesis and domain understanding by raising nuanced questions regarding health economics, life valuation, and downstream behavior changes associated with chronic non-curative treatments.

the scores for every segment, with the reasoning behind each

Topic	The host as informed peer	Guest teaching	Guest disagreement	The host pushing back	Why
Overview of Big Ideas 2024	0	2	0	0	Monologue intro consisting of voiceover marketing disclaimers followed by guest Julie Yoo introducing her big idea about democratizing miracle drugs. Because this is a scripted monologue segment without active host questioning, host expertise and pushback are scored zero.
Understanding GLP-1 Agonists and Their Impact	2	6	1	0	The host asks a standard conversational prompt about GLP-1 drugs. Guest Julie Yoo educates the host and audience on GLP-1 hormone biology, diabetes prevalence, weight loss mechanisms, and cardiovascular benefits.
Adoption Challenges and Insurance Coverage for GLP-1s	2	6	0	0	The host prompts with statistics on diabetes and obesity, asking how many people actually access GLP-1s. The guest educates with comparative statistics regarding Humira baseline claims versus GLP-1 claims and immature insurance coverage.
The Promise and Complexity of Cell and Gene Therapies	2	6	1	0	The host asks for examples of curative cell and gene therapies. The guest gently reframes cell and gene therapies as an even more extreme operational and financial challenge than GLP-1s, detailing sickle cell and cancer treatments.
System Bottlenecks in Financing and Operations	3	7	0	0	The host synthesizes the dual problem of breaking versus bankrupting the healthcare system. The guest provides a high-level masterclass on the misalignment between multi-million dollar upfront drug costs and average 3-4 year employee insurance tenure.
Financial Realities and Time Horizons for Chronic Treatments	4	5	0	0	The host articulates thoughtful questions around the valuation of life and downstream cardiovascular/lifestyle effects for non-curative GLP-1s. The guest educates on monthly recurring costs compared to standard daily blood pressure pills.
Emerging Startup Opportunities Across Healthcare Infrastructure	2	6	0	0	The host asks a compound concluding question on solutions, roadblocks, and policy. The guest outlines four specific startup innovation categories and explains the industry cold start problem.
The Role of Regulation and Policy in Scaling Access	3	5	0	1	The host politely pushes back to re-focus on the policy aspect after it was skipped in the previous response, asking whether market innovation alone suffices. The guest outlines FDA and CMS regulatory roles.
Future Episode Teasers and Conclusion	0	0	0	0	Brief voiceover outro previewing future podcast episodes and concluding the segment. As a solo wrap-up, host expertise and guest dynamic scores are zero.

Statements from this episode (12)

Assertion Not checkable as stated

Yoo: US healthcare system cannot bear costs of breakthrough therapies

“Our current healthcare insurance system is just not set up to bear the cost of these therapies, or to accurately gauge their value, given that some are curative, nor are our healthcare providers prepared to manage the complex logistics, data collection, and cl…”

Julie Yoo Dec 11, 2023 ▶ 2:00

Assertion Supported

Julie Yoo: Type 2 diabetes affects over 11% of Americans

“It affects over 11% of us, and so one in 10 of the people that you know are likely to be diagnosed with type two diabetes at some point in their life.”

Julie Yoo Dec 11, 2023 ▶ 3:19

Assertion Supported

Julie Yoo: Obesity affects 42% of the American population

“Sadly, it affects 42% of the American population, which is remarkable”

Julie Yoo Dec 11, 2023 ▶ 4:01

Assertion Supported

Yoo: Humira was history's best-selling US drug, treating 300,000 annually

“There's a drug called Humira, which was the best-selling drug ever in the history of American drug industry, and that drug was used by roughly 300,000 Americans each year”

Julie Yoo Dec 11, 2023 ▶ 6:00

Assertion Supported

Yoo: GLP-1s logged 3.6 million US prescription claims in 2022

“In the case of GLP-I's there was a study that showed in 2022, Based on prescription claims data analysis that there was roughly, ah, a 3.6 million prescription claims for GLP ones in that year.”

Julie Yoo Dec 11, 2023 ▶ 6:22

Assertion Supported

Yoo: Only 25% of employer health plans cover GLP-1 drugs

“It's probably only about a fourth, 25% of employer sponsored insurance plans that today cover these drugs in terms of the benefit.”

Julie Yoo Dec 11, 2023 ▶ 7:44

Prediction Held up

Yoo: Dozens of cell and gene therapies will reach market soon

“There are dozens of drugs of this ilk that are projected to be approved and brought onto the market in the next several years”

Julie Yoo Dec 11, 2023 ▶ 11:00

Assertion Supported

Yoo: Cell and gene therapies cost $2M to $3M upfront

“Some of these cell and gene therapies that I mentioned can, it can be a one-time cost of, you know, two to three million dollars, and sometimes more.”

Julie Yoo Dec 11, 2023 ▶ 11:57

Assertion Supported

Yoo: GLP-1 drugs cost health plans roughly $1,000 per month

“So GOP ones are also relatively expensive, cheaper than cell and gene therapies, but we're talking, you know, a thousand dollars a month, roughly speaking for this class of drugs.”

Julie Yoo Dec 11, 2023 ▶ 16:01

Prediction Held up

Yoo: Cheaper GLP-1 alternatives expected to be approved within years

“There is actually hope that there's a whole pipeline of cheaper versions of the current GLP-ONE therapies that are in the pipeline expected to be approved in the next several years”

Julie Yoo Dec 11, 2023 ▶ 17:01

Assertion Not checkable as stated

Yoo: Drug makers lack post-market data feedback loops for prescriptions

“That is unfortunately like the state of affairs for many drugs that we have on the market today is that once the drug is prescribed and it's out there, there's not really great ways for the biomanufacturing companies to get feedback back.”

Julie Yoo Dec 11, 2023 ▶ 18:59

Prediction Not checkable as stated

Yoo: CMS will launch payment guidance for breakthrough therapies despite election delays

“And then CMS, which administers Medicare and Medicaid the government sponsored insurance programs in our country. They generally tend to be at the tip of the spear of any payment innovation for new classes of drugs and new classes of services. And so the expec…”

Julie Yoo Dec 11, 2023 ▶ 21:41

Big Ideas in 2024: Democratizing “Miracle Drugs” with Julie Yoo

How this conversation actually went

Statements from this episode (12)

Turn any episode into a week of clips.